Searchable abstracts of presentations at key conferences in endocrinology

ea0090ep675 | Pituitary and Neuroendocrinology | ECE2023

Metabolic and surgical outcomes of adult patients with craniopharyngiomapatients undergoing extended transsphenoidal surgery (ETS) at a referral center

Pinar Gutierrez Ana , Dios Elena , Venegas-Moreno Eva , Remon Pablo , Oulad Ahmed Bothayna , Kaen Ariel , Cardenas Eugenio , Fajardo Elena , Cano Gonzales David , Soto-Moreno Alfonso

Objectives: To describe the metabolic and surgical outcomes of adult patients with craniopharyngioma undergoing extended transsphenoidal surgery (ETS). Secondary: to compare surgical outcomes with patients undergoing conventional transcranial surgery (CTS).Methods: Retrospective observational study. Adult patients with craniopharyngiomas undergoing ETS between 2015 and 2020 were included. Descriptive analysis was performed by obtaining median and quartil...

ea0063p1087 | Pituitary and Neuroendocrinology 3 | ECE2019

Surgical outcomes in cushing disease: Endoscopic transsphenoidal pituitary surgery

Remon-Ruiz Pablo , Dios-Fuentes Elena , Venegas Eva , Cozar-Duenas Miriam , Kaen Ariel , Cardenas Eugenio , Gonzalez Natividad , Martin Ignacio , Roldan Florinda , Fajardo Elena , Cano David , Soto-Moreno Alfonso

Introduction: Endoscopic transsphenoidal pituitary surgery has become the first line method for removal pituitary tumours. A new way to see the surgical field and the cooperation of two neurosurgeons has supposed a revolution in the area.Objetives: Analyse surgical outcomes and complications of a cohort of patients from a single center who underwent ETPS for Cushing disease.Methods: Descriptive prospective-retrospective study inclu...

ea0063p1091 | Pituitary and Neuroendocrinology 3 | ECE2019

Surgical outcomes in acromegaly disease: endoscopic transsphenoidal pituitary surgery

Cozar Miriam , Remon-Ruiz Pablo , Dios-Fuentes Elena , Cozar Miriam , Kaen Ariel , Cardenas Eugenio , Gonzalez Natividad , Martin Ignacio , Roldan Florinda , Fajardo Elena , Cano David , Soto-Moreno Alfonso

Introduction: Endoscopic transsphenoidal pituitary surgery has become the first line method for removal pituitary tumours. A new way to see the surgical field and the cooperation of two neurosurgeons has supposed a revolution in the area.Objetives: Analyse surgical outcomes and complications of a cohort of patients from a single center who underwent ETPS for GH secreting pituitary tumours.Methods: Descriptive prospective-retrospect...

ea0056p756 | Neuroendocrinology | ECE2018

Pituitary abscesses diagnosis and therapeutic approach in a reference unit

Cozar Miriam , Venegas Eva , Dios Elena , Cano David , Madrazo Ainara , Remon Pablo , Jimenez Enrique , Roldan Florinda , Cardenas Eugenio , Kaen Ariel , Soto Alfonso

Introduction: Pituitary abscess (PA) is a rare condition, representing less than 1% of pituitary lessions. Only around 200 cases have been reported in the scientific literature. Preoperative diagnosis is often challenging due to nonspecific clinical and radiological manifestations.Materials and methods: Retrospective descriptive cohort study. We analyze demographic and clinical variables, hormonal involvement, recurrence, type of surgery and antibiotic t...

ea0056p768 | Neuroendocrinology | ECE2018

ACTH-secreting pituitary adenomas surgical outcomes and complications in Endoscopic transsphenoidal pituitary surgery (ETPS)

Remon-Ruiz Pablo , Dios-Fuentes Elena , Venegas Eva , Kaen Ariel , Cardenas Eugenio , Garcia Natividad , Roldan Florinda , Fajardo Elena , Cano David , Soto Alfonso

Methods: Descriptive retrospective study among patients who underwent ETPS for ACTH-secreting pituitary adenomas performed by the same surgical team from January/2013 to January/2017.Results: 27 ACTH-secreting pituitary adenomas operated via ETPS. 20 (74.1%) were women, median age at surgery was 43.25 [29.65–61.59] years and median follow-up was 3.13 [1.6–6.69] years. Presurgically, 25 (92.59%) patients recieved drugs for control cortisol hyper...

ea0056p769 | Neuroendocrinology | ECE2018

Clinical outcomes and complications in Endoscopic transsphenoidal pituitary surgery (ETPS) for Non-functioning pituitary adenomas

Remon-Ruiz Pablo , Dios Elena , Venegas Eva , Cardenas Eugenio , Kaen Ariel , Garcia Natividad , Roldan Florinda , Fajardo Elena , Cano David , Soto Alfonso

Methods: We conducted a retrospective descriptive study including 67 patients with non-functioning pituitary adenomas surgicaly removed via ETPS beetwen January/2013 to January/2017.Results: Among 67 patients with non-functioning pituitary adenomas surgicaly removed via ETPS 44 (65.67%) were men. 52 (77.61%) patients recieved their first surgery, 14 (20.9%) had been operated one time before and 1 (1.49%) had been operated two times. Every patient reopera...

ea0090p542 | Late-Breaking | ECE2023

Characterization of RNA expression and clinical outcomes in patients with aggresive pituitary tumors treated with temozolomide

Venegas Moreno Eva , Remon Pablo , Dios-Fuentes Elena , Pinar Gutierrez Ana , Manuel Canelo Juan , Oliva Rosario , Alonso-Garcia Miriam , Cardenas Eugenio , Kaen Ariel , G-Garcia Miguel E. , Cano Gonzales David , Luque Raul M. , Soto-Moreno Alfonso

Methods: Descriptive retrospective study of the clinical outcomes and RNA expression in aggressive pituitary tumors treated with temozolomide. RNA expression was studied in tumor samples normalized to housekeeping genes including GH, POMC, PRL, αsub, FSH, LH, TSH, sst1, sst2, sst3, sst5, sst5b, sst5c, DR1, DR2T, DR2L, DR4, DR5, Ghrelin, In1-Ghrelin, GOAT, GHRR1b, AVPR1b, GHRH-R, GnRH-R, Ki-67, PTTG1, CRHR1.Results: Ten patients were treated. 30% (3)...

ea0037ep701 | Pituitary: basic and neuroendocrinology | ECE2015

Clinical and molecular differences between invasive and non-invasive pituitary adenomas

Cano David , Mendez-Muros Mariola , Venegas-Moreno Eva Maria , Gros Noelia , Dios Elena , Garcia-Hernandez Natividad , Madrazo-Atutxa Ainara , Martin Ignacio , Cardenas Eugenio , Kaen Ariel , Roldan Florinda , Soto-Moreno Alfonso

Pituitary adenomas are usually benign. However, a significant number of pituitary adenomas show an aggressive behaviour, with local invasion, increased risk of recurrence after surgery and lack of therapeutic response. In this study, we aimed to determine whether invasive and non-invasive pituitary adenomas display differences in clinical features and molecular parameters. In this retrospective descriptive study, 46 pituitary adenomas were analysed. Invasiveness was defined as...

ea0070aep687 | Pituitary and Neuroendocrinology | ECE2020

Endoscopic transsphenoidal pituitary surgery (ETPS) for pituitary tumors: Outcomes and complications

Venegas-Moreno Eva , Remon Pablo , Dios-Fuentes Elena , Deniz-Garcia Alejandro , Cardenas Eugenio , Kaen Ariel , Martin-Schrader Ignacio , Gonzalez-Rivera Natividad , Roldan Florinda , Cano-Gonzalez David , Soto-Moreno Alfonso

Methods: Restrospective descriptive study of patients who underwent ETPS for pituitary adenoma removal performed by the same surgical team in Virgen del Rocio Hospital of Seville from January 2014 to January 2019.Results: 174 patients had a pituitary adenoma (44 GH, 36 ACTH, 94 Non functioning). 54.02% were female. In acromegaly, 39 (88.63%) patients were operated by ETPS as initial approach. 20 (51.28%) patients had cavernous sinus invation. At outcome ...

ea0056gp196 | Pituitary Basic | ECE2018

E-cadherin expression is associated with the response to somatostatin analogues in patients with acromegaly

Cano David A , Venegas-Moreno Eva , Gros-Herguido Noelia , Dios Elena , Flores-Martinez Alvaro , Gonzalez Natividad , Madrazo-Atutxa Ainara , Cardenas Eugenio , Kaen Ariel , Castano Justo P , Luque Raul M , Soto-Moreno Alfonso

Aim: To assess whether E-cadherin expression levels in somatotropinomas were associated with the response to somatostatin analogues (SSAs) therapy in patients with acromegaly.Methods: In this retrospective study, 56 acromegaly patients that underwent transsphenoidal surgery were evaluated. All patients were treated preoperatively with SSAs (octreotide or lanreotide) for at least 6 months. Responsiveness to SSAs was evaluated by percent IGF-1 reduction af...